ARTICLE | Emerging Company Profile

Coronado: Cancer conquistador

July 14, 2008 7:00 AM UTC

Coronado Biosciences Inc. has in-licensed cancer candidates that it hopes will improve on the safety profiles of existing drugs. The company initially is targeting small indications to show clinical utility in an effort to attract partners for the pricier development for larger markets.

The company’s lead candidate is CNDO101, a fourth-generation anthracycline in Phase I testing to treat solid tumors. Anthracyclines are one of the most effective classes of chemotherapeutics. Although they are used to treat a wide variety of cancers, they are cardiotoxic and can cause vomiting...